ArticleGut and liver2013
Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score.
Article in Gut and liver, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.Frontiers in nutrition · 2024Pooled it
- Performance of Simple Outpatient-based Biomarker Panels for Screening of Steatotic Liver Disease in Women with Morbid Obesity from Southern India.TouchREVIEWS in endocrinology · 2025Article
- Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.Lipids in health and disease · 2025Review
- Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.Clinical and molecular hepatology · 2023Review
- Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease.Scientific reports · 2021Article
- Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease.Scientific reports · 2021Article
- Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.Chinese medical journal · 2020Article
- Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease.Gut and liver · 2017Article
- Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.Digestive diseases and sciences · 2016 · on this mapReview
- Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis.Gut and liver · 2016Article
- Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?Current hepatology reports · 2015Article
- Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.World journal of hepatology · 2015Review
- Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.International journal of endocrinology · 2015Review
- Comments to prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD score.Gut and liver · 2014Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe BARD score is a model to detect advanced liver fibrosis in nonalcoholic fatty liver disease (NAFLD) patients. The aims of this study were to identify additional factors and then to build an enhanced version of the BARD score.
methodsOne hundred seven patients with biopsy-proven NAFLD were enrolled retrospectively. Logistic regressions were performed to identify independent risk factors for advanced liver fibrosis (stage 3 or 4). An enhanced model of the BARD score (BARDI score) was built and evaluated with a receiver operating characteristic (ROC) curve.
resultsIn multivariate analysis, age (odds ratio [OR], 0.89; p=0.04), aspartate aminotransferase/alanine aminotransferase ratio (OR, 1.73; p<0.01), and international normalized ratio (INR) (OR, 8.85; p<0.01) were independently significant factors. The BARDI score was created by adding the INR to the BARD. The area under the ROC curve of the BARDI score was significantly larger than that of the BARD score (0.881 vs 0.808, p<0.01). A BARDI score of 3 or more showed a positive predictive value (PPV) of 51.0% and a negative predictive value (NPV) of 96.0%.
conclusionsThe BARDI score had an improved PPV over the BARD score and maintained an excellent NPV. Further study is warranted for its external validation and comparison with other models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.